September 2025
1. TAN S, He H, Ni J, Guo Y, et al
   Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary ce
   Cancer. 2025;131:e70083.
   

   >> Share

   
   
2. NIERENGARTEN MB
   Safety and promising efficacy with enhanced CAR T-cell therapy for lymphoma.
   Cancer. 2025;131:e70035.
   

   >> Share

   
   June 2025
3. 
   Correction to "Surveillance imaging during first remission in follicular lymphoma does not impact overall survival".
   Cancer. 2025;131:e35934.
   

   >> Share

   
   
4. NIERENGARTEN MB
   Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma.
   Cancer. 2025;131:e35899.
   

   >> Share

   
   
5. 
   Correction to "Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study".
   Cancer. 2025;131:e35933.
   

   >> Share

   
   March 2025
6. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
   The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
   Cancer. 2025;131:e35804.
   

   >> Share

   
   
7. JIMENEZ MUNARRIZ BE, Khan S, Li Y, Ghazali N, et al
   Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment.
   Cancer. 2025;131 Suppl 1:e35786.
   

   >> Share

   
   January 2025
8. YIN X, He Q, Liu D, Xie L, et al
   Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.
   Cancer. 2025;131:e35697.
   

   >> Share

   
   
9. GAO Y, Huang Y, Zhang Q, Yang H, et al
   Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.
   Cancer. 2025;131:e35672.
   

   >> Share

   
   November 2024
10. HANZLIK E, Sabin ND, Yoshida T, Delaney A, et al
    Sexual dysfunction among long-term survivors of Hodgkin lymphoma.
    Cancer. 2024 Nov 7. doi: 10.1002/cncr.35637.
    

    >> Share

    
    
11. LI Z, Li X, Li S, Tao R, et al
    Preclinical evaluation and phase 1 study of the PI3Kalpha/delta inhibitor TQ-B3525 in Chinese patients with advanced cancers.
    Cancer. 2024;130:3686-3698.
    

    >> Share

    
    October 2024
12. NIERENGARTEN MB
    Multitargeted therapy is safe and leads to durable remission of DLBCL.
    Cancer. 2024;130:3238.
    

    >> Share

    
    August 2024
13. ZENG C, Wei Z, Huang J, Zhu J, et al
    Effect of body mass index on the prognosis of children and adolescents with high-grade mature B-cell non-Hodgkin lymphoma.
    Cancer. 2024 Aug 22. doi: 10.1002/cncr.35536.
    

    >> Share

    
    June 2024
14. HSU YT, Wu SJ, Kao HW, Hsiao SY, et al
    Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
    Cancer. 2024;130:1972-1981.
    

    >> Share

    
    May 2024
15. LI ZH, Zhang MY, Federico M, Civallero M, et al
    Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: A population-based analysis and validation.
    Cancer. 2024 May 29. doi: 10.1002/cncr.35378.
    

    >> Share

    
    April 2024
16. NIERENGARTEN MB
    Golidocitinib favorable for relapsed/refractory T-cell lymphoma.
    Cancer. 2024;130:1191-1192.
    

    >> Share

    
    
17. LI A, Yi H, Deng S, Ruan M, et al
    The genetic landscape of histologically transformed marginal zone lymphomas.
    Cancer. 2024;130:1246-1256.
    

    >> Share

    
    
18. GIRI S, Harmon C, Landier W, Chen Y, et al
    Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35298.
    

    >> Share

    
    February 2024
19. WU S, Rhee JW, Iukuridze A, Bosworth A, et al
    Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.
    Cancer. 2024 Feb 15. doi: 10.1002/cncr.35252.
    

    >> Share

    
    
20. TZANKOV A, Tatarczuch M
    Time to Be Launched 1 auXiliary Risk strat1fier in marginal zone lymphoma transformation: TBL1XR1.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35246.
    

    >> Share

    
    January 2024
21. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    

    >> Share

    
    December 2023
22. DAI L, Chen H, Tan Q, Wang Y, et al
    Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
    Cancer. 2023 Dec 22. doi: 10.1002/cncr.35158.
    

    >> Share

    
    
23. CHU Y, Liu Y, Yu Z, Zhan L, et al
    Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
    Cancer. 2023 Dec 2. doi: 10.1002/cncr.35137.
    

    >> Share

    
    November 2023
24. GORDON MJ, Feng L, Strati P, Lee HJ, et al
    Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35114.
    

    >> Share

    
    
25. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share